<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00053703</url>
  </required_header>
  <id_info>
    <org_study_id>U01 MH 615218-01A</org_study_id>
    <secondary_id>U01MH062726</secondary_id>
    <secondary_id>U01MH061355-01A1</secondary_id>
    <secondary_id>U01MH062726-01</secondary_id>
    <secondary_id>U01MH061464-01A1</secondary_id>
    <nct_id>NCT00053703</nct_id>
    <nct_alias>NCT00030251</nct_alias>
    <nct_alias>NCT00043290</nct_alias>
  </id_info>
  <brief_title>Treatment of Early Onset Schizophrenia Spectrum Disorders (TEOSS)</brief_title>
  <acronym>TEOSS</acronym>
  <official_title>Treatment of Schizophrenia and Related Disorders in Children and Adolescents</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of North Carolina, Chapel Hill</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Mental Health (NIMH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of North Carolina, Chapel Hill</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the safety and efficacy of risperidone (Risperdal®), olanzapine
      (Zyprexa®), and molindone (Moban®) for the treatment of children and adolescents with
      schizophrenia or schizoaffective disorder.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Little research has been conducted on the use of psychotropic agents in children and
      adolescents with early onset schizophrenia spectrum disorders. This study will compare
      antipsychotic agents with different mechanisms of action in children and adolescents who have
      schizophrenia or schizoaffective disorder with active psychotic symptoms.

      Participants are randomly assigned to receive risperidone (Risperdal), olanzapine (Zyprexa),
      or molindone (Moban) for 8 weeks. After 11/2005, no additional patients will be assigned to
      olanzapine treatment. Patients with significant improvement and without side effects continue
      maintenance therapy for another 44 weeks. Participants who show significant negative symptoms
      after 8 weeks may be started on a mood stabilizer or antidepressant. Weight gain, metabolic
      changes, neurocognition, functional outcome, psychotic symptoms, extrapyramidal side effects,
      and the ability to sustain effective therapy over time are assessed.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2002</start_date>
  <completion_date type="Actual">May 2007</completion_date>
  <primary_completion_date type="Actual">May 2007</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at 8 Weeks</measure>
    <time_frame>8 weeks</time_frame>
    <description>Assessed with the Positive and Negative Syndrome Scale in which a clinician rates various psychotic symptoms on the basis of observation of the participant, interview with the participant, and review of all other available information including informant reports. The scale consists of 30 items which are rated categorically between 1 - no symptoms to 7 - extreme symptoms. The minimal score is 0 and the maximal score is 210, with higher scores reflecting more symptoms. Typically scores &gt; that 60 are considered clinically significant.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in PANSS Positive Symptom Subscale Score at 8 Weeks.</measure>
    <time_frame>8 weeks</time_frame>
    <description>The PANSS (described above) includes 7 items that reflect positive psychotic symptoms such as hallucinations and delusions. As are all items within the PANSS, items are categorically rated by the clinician between 0 - no symptoms to 7 extreme symptoms. The minimal score is 0 reflecting no positive symptoms to 49 reflecting that all items were extreme. Higher scores reflect more severe symptoms. Scores above 18 are usually clinically significant.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in PANSS Negative Symptom Subscale at Week 8</measure>
    <time_frame>8 weeks</time_frame>
    <description>The PANSS (described above) includes 7 items that reflect negative psychotic symptoms such as amotivation and social withdrawal. As are all items within the PANSS, items are categorically rated by the clinician between 0 - no symptoms to 7 extreme symptoms. The minimal score is 0 reflecting no positive symptoms to 49 reflecting that all items were extreme. Higher scores reflect more severe symptoms. Scores above 18 are usually clinically significant.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Weight at Week 8</measure>
    <time_frame>8 weeks</time_frame>
    <description>change in weight from baseline to week 8 in kg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Barnes Akathisia Scale at Week 8</measure>
    <time_frame>8 weeks</time_frame>
    <description>Barnes Akathisia Scale is a clinician rated scale which considers information based on observation of the participant as well as participant report. The scale includes 3 items rated between 0- none to 3 severe and 1 summary item rated between 0 none to 5 severe. All items are summed to obtain the total score. The minimal total score is 0 and the maximal score is 14 with higher scores reflecting more severe akathisia. A score of 4 or more is clinically significant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Body Mass Index Change, kg/m2, at Week 8</measure>
    <time_frame>8 weeks</time_frame>
    <description>Change from baseline in Body Mass Index Change, kg/m2, at week 8, last observation was carried forward for individuals who withdrew from treatment early.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">116</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>olanzapine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>oral olanzapine 5-20mg per day for up to 52 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>risperidone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>oral risperidone 0.5mg to 6mg daily for up to 52 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>molindone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>oral molindone from 10-140mg/daily for up to 52 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Risperidone</intervention_name>
    <description>oral risperidone 0.5mg to 6mg daily for up to 52 weeks</description>
    <arm_group_label>risperidone</arm_group_label>
    <other_name>Risperdal</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olanzapine (enrollment closed in this treatment)</intervention_name>
    <description>oral olanzapine 5-20mg per day for up to 52 weeks</description>
    <arm_group_label>olanzapine</arm_group_label>
    <other_name>Zyprexa</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Molindone</intervention_name>
    <description>oral molindone from 10-140mg/daily for up to 52 weeks</description>
    <arm_group_label>molindone</arm_group_label>
    <other_name>Moban</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Schizophrenia, schizophreniform disorder, or schizoaffective disorder with psychotic
             symptoms

          -  Free of depot antipsychotic medication for at least 6 months. Oral antipsychotic
             medication at entry into the study is allowed, provided the participant has not had an
             adequate trial during the present episode of psychosis.

          -  If taking antidepressant or mood stabilizing medication, stable dosing for at least 30
             days prior to entry.

          -  Good physical health

        Exclusion Criteria:

          -  Risperidone (RIS), olanzapine (OLA)*, or molindone (MOL) for 8 weeks or more during
             THIS episode, with 2 weeks at the maximal dose (6 mg/day of RIS, 20 mg/day of OLA, or
             140 mg/day of MOL)

          -  If using antidepressant and/or mood stabilizing medications, treatment for fewer than
             30 days immediately before entry

          -  Intolerance or nonresponse to RIS, OLA*, or MOL during any previous treatment

          -  Bipolar affective disorder,post traumatic stress disorder, personality disorder, or
             psychosis not otherwise specified

          -  Currently meeting Diagnostic and Statistical Manual version IV (DSM IV) criteria for
             major depression episode

          -  DSM IV criteria for substance abuse or dependence with intention to continue illicit
             substance abuse

          -  Endocrinological or neurological conditions which confound the diagnosis or are a
             contraindication to treatment with antipsychotics

          -  Mental retardation

          -  Risk of suicide or homicide that is not adequately controlled in the current setting

          -  Pregnancy or refusal to practice contraception during the study

        &quot;*&quot; OLA exclusion not applicable after 11/2005
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>8 Years</minimum_age>
    <maximum_age>19 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Linmarie Sikich, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>University of North Carolina, Chapel Hill</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cambridge Health Alliance</name>
      <address>
        <city>Medford</city>
        <state>Massachusetts</state>
        <zip>02155</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of North Carolina</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27514</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospitals of Cleveland</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>McClellan J, Sikich L, Findling RL, Frazier JA, Vitiello B, Hlastala SA, Williams E, Ambler D, Hunt-Harrison T, Maloney AE, Ritz L, Anderson R, Hamer RM, Lieberman JA. Treatment of early-onset schizophrenia spectrum disorders (TEOSS): rationale, design, and methods. J Am Acad Child Adolesc Psychiatry. 2007 Aug;46(8):969-78.</citation>
    <PMID>17667476</PMID>
  </results_reference>
  <results_reference>
    <citation>Frazier JA, McClellan J, Findling RL, Vitiello B, Anderson R, Zablotsky B, Williams E, McNamara NK, Jackson JA, Ritz L, Hlastala SA, Pierson L, Varley JA, Puglia M, Maloney AE, Ambler D, Hunt-Harrison T, Hamer RM, Noyes N, Lieberman JA, Sikich L. Treatment of early-onset schizophrenia spectrum disorders (TEOSS): demographic and clinical characteristics. J Am Acad Child Adolesc Psychiatry. 2007 Aug;46(8):979-88.</citation>
    <PMID>17667477</PMID>
  </results_reference>
  <results_reference>
    <citation>Findling RL, Johnson JL, McClellan J, Frazier JA, Vitiello B, Hamer RM, Lieberman JA, Ritz L, McNamara NK, Lingler J, Hlastala S, Pierson L, Puglia M, Maloney AE, Kaufman EM, Noyes N, Sikich L. Double-blind maintenance safety and effectiveness findings from the Treatment of Early-Onset Schizophrenia Spectrum (TEOSS) study. J Am Acad Child Adolesc Psychiatry. 2010 Jun;49(6):583-94; quiz 632. doi: 10.1016/j.jaac.2010.03.013. Epub 2010 May 1.</citation>
    <PMID>20494268</PMID>
  </results_reference>
  <verification_date>February 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 4, 2003</study_first_submitted>
  <study_first_submitted_qc>February 4, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 5, 2003</study_first_posted>
  <results_first_submitted>September 16, 2013</results_first_submitted>
  <results_first_submitted_qc>February 7, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 26, 2014</results_first_posted>
  <last_update_submitted>February 7, 2014</last_update_submitted>
  <last_update_submitted_qc>February 7, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 26, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of North Carolina, Chapel Hill</investigator_affiliation>
    <investigator_full_name>Linmarie Sikich, MD</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Psychotic Disorders</keyword>
  <keyword>Schizophreniform Disorder</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Risperidone</mesh_term>
    <mesh_term>Olanzapine</mesh_term>
    <mesh_term>Molindone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>From February 2002 to May 2006, youth were screened at four academic sites: University of North Carolina at Chapel Hill, McLean Hospital and Cambridge Health Alliance at Harvard Medical School, University of Washington, and Case Western Reserve University.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Olanzapine</title>
          <description>oral olanzapine 5-20mg per day for up to 52 weeks</description>
        </group>
        <group group_id="P2">
          <title>Risperidone</title>
          <description>oral risperidone 0.5mg to 6mg daily for up to 52 weeks</description>
        </group>
        <group group_id="P3">
          <title>Molindone</title>
          <description>oral molindone from 10-140mg/daily for up to 52 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
                <participants group_id="P2" count="41"/>
                <participants group_id="P3" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="28"/>
                <participants group_id="P3" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="15"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>We are referring to the population of participants who had baseline assessment, took at least one dose of trial medication, and had at least one post-baseline assessment. There were 3 randomized subjects, on in each treatment group, who did not take at least one dose of study medication and are not included.</population>
      <group_list>
        <group group_id="B1">
          <title>Olanzapine</title>
          <description>oral olanzapine 5-20mg per day for up to 52 weeks</description>
        </group>
        <group group_id="B2">
          <title>Risperidone</title>
          <description>oral risperidone 0.5mg to 6mg daily for up to 52 weeks</description>
        </group>
        <group group_id="B3">
          <title>Molindone</title>
          <description>oral molindone from 10-140mg/daily for up to 52 weeks</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="35"/>
            <count group_id="B2" value="41"/>
            <count group_id="B3" value="40"/>
            <count group_id="B4" value="116"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="39"/>
                    <measurement group_id="B4" value="114"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13.84" spread="2.41"/>
                    <measurement group_id="B2" value="14.54" spread="2.38"/>
                    <measurement group_id="B3" value="14.3" spread="2.4"/>
                    <measurement group_id="B4" value="14.25" spread="2.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="23"/>
                    <measurement group_id="B4" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="41"/>
                    <measurement group_id="B3" value="40"/>
                    <measurement group_id="B4" value="116"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at 8 Weeks</title>
        <description>Assessed with the Positive and Negative Syndrome Scale in which a clinician rates various psychotic symptoms on the basis of observation of the participant, interview with the participant, and review of all other available information including informant reports. The scale consists of 30 items which are rated categorically between 1 - no symptoms to 7 - extreme symptoms. The minimal score is 0 and the maximal score is 210, with higher scores reflecting more symptoms. Typically scores &gt; that 60 are considered clinically significant.</description>
        <time_frame>8 weeks</time_frame>
        <population>All randomized patients who took at least one dose of drug and had at least one post-baseline assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Olanzapine</title>
            <description>oral olanzapine 5-20mg per day for up to 52 weeks</description>
          </group>
          <group group_id="O2">
            <title>Risperidone</title>
            <description>oral risperidone 0.5mg to 6mg daily for up to 52 weeks</description>
          </group>
          <group group_id="O3">
            <title>Molindone</title>
            <description>oral molindone from 10-140mg/daily for up to 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at 8 Weeks</title>
          <description>Assessed with the Positive and Negative Syndrome Scale in which a clinician rates various psychotic symptoms on the basis of observation of the participant, interview with the participant, and review of all other available information including informant reports. The scale consists of 30 items which are rated categorically between 1 - no symptoms to 7 - extreme symptoms. The minimal score is 0 and the maximal score is 210, with higher scores reflecting more symptoms. Typically scores &gt; that 60 are considered clinically significant.</description>
          <population>All randomized patients who took at least one dose of drug and had at least one post-baseline assessment.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="41"/>
                <count group_id="O3" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-26.6" spread="17.8"/>
                    <measurement group_id="O2" value="-23.7" spread="25.5"/>
                    <measurement group_id="O3" value="-27.0" spread="17.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.05</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Weight at Week 8</title>
        <description>change in weight from baseline to week 8 in kg</description>
        <time_frame>8 weeks</time_frame>
        <population>All randomized patients who took at least one dose of drug and had at least one post-baseline assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Olanzapine</title>
            <description>oral olanzapine 5-20mg per day for up to 52 weeks</description>
          </group>
          <group group_id="O2">
            <title>Risperidone</title>
            <description>oral risperidone 0.5mg to 6mg daily for up to 52 weeks</description>
          </group>
          <group group_id="O3">
            <title>Molindone</title>
            <description>oral molindone from 10-140mg/daily for up to 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Weight at Week 8</title>
          <description>change in weight from baseline to week 8 in kg</description>
          <population>All randomized patients who took at least one dose of drug and had at least one post-baseline assessment.</population>
          <units>Kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="41"/>
                <count group_id="O3" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.12" spread="3.60"/>
                    <measurement group_id="O2" value="3.64" spread="3.95"/>
                    <measurement group_id="O3" value="0.34" spread="2.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Barnes Akathisia Scale at Week 8</title>
        <description>Barnes Akathisia Scale is a clinician rated scale which considers information based on observation of the participant as well as participant report. The scale includes 3 items rated between 0- none to 3 severe and 1 summary item rated between 0 none to 5 severe. All items are summed to obtain the total score. The minimal total score is 0 and the maximal score is 14 with higher scores reflecting more severe akathisia. A score of 4 or more is clinically significant.</description>
        <time_frame>8 weeks</time_frame>
        <population>All randomized patients who took at least one dose of drug and had at least one post-baseline assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Olanzapine</title>
            <description>oral olanzapine 5-20mg per day for up to 52 weeks</description>
          </group>
          <group group_id="O2">
            <title>Risperidone</title>
            <description>oral risperidone 0.5mg to 6mg daily for up to 52 weeks</description>
          </group>
          <group group_id="O3">
            <title>Molindone</title>
            <description>oral molindone from 10-140mg/daily for up to 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Barnes Akathisia Scale at Week 8</title>
          <description>Barnes Akathisia Scale is a clinician rated scale which considers information based on observation of the participant as well as participant report. The scale includes 3 items rated between 0- none to 3 severe and 1 summary item rated between 0 none to 5 severe. All items are summed to obtain the total score. The minimal total score is 0 and the maximal score is 14 with higher scores reflecting more severe akathisia. A score of 4 or more is clinically significant.</description>
          <population>All randomized patients who took at least one dose of drug and had at least one post-baseline assessment.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="41"/>
                <count group_id="O3" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.19" spread="2.12"/>
                    <measurement group_id="O2" value="0.41" spread="2.37"/>
                    <measurement group_id="O3" value="1.23" spread="3.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in PANSS Positive Symptom Subscale Score at 8 Weeks.</title>
        <description>The PANSS (described above) includes 7 items that reflect positive psychotic symptoms such as hallucinations and delusions. As are all items within the PANSS, items are categorically rated by the clinician between 0 - no symptoms to 7 extreme symptoms. The minimal score is 0 reflecting no positive symptoms to 49 reflecting that all items were extreme. Higher scores reflect more severe symptoms. Scores above 18 are usually clinically significant.</description>
        <time_frame>8 weeks</time_frame>
        <population>All randomized patients who took at least one dose of drug and had at least one post-baseline assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Olanzapine</title>
            <description>oral olanzapine 5-20mg per day for up to 52 weeks</description>
          </group>
          <group group_id="O2">
            <title>Risperidone</title>
            <description>oral risperidone 0.5mg to 6mg daily for up to 52 weeks</description>
          </group>
          <group group_id="O3">
            <title>Molindone</title>
            <description>oral molindone from 10-140mg/daily for up to 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in PANSS Positive Symptom Subscale Score at 8 Weeks.</title>
          <description>The PANSS (described above) includes 7 items that reflect positive psychotic symptoms such as hallucinations and delusions. As are all items within the PANSS, items are categorically rated by the clinician between 0 - no symptoms to 7 extreme symptoms. The minimal score is 0 reflecting no positive symptoms to 49 reflecting that all items were extreme. Higher scores reflect more severe symptoms. Scores above 18 are usually clinically significant.</description>
          <population>All randomized patients who took at least one dose of drug and had at least one post-baseline assessment.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="41"/>
                <count group_id="O3" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.9" spread="6.0"/>
                    <measurement group_id="O2" value="-8.4" spread="8.1"/>
                    <measurement group_id="O3" value="-8.8" spread="5.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in PANSS Negative Symptom Subscale at Week 8</title>
        <description>The PANSS (described above) includes 7 items that reflect negative psychotic symptoms such as amotivation and social withdrawal. As are all items within the PANSS, items are categorically rated by the clinician between 0 - no symptoms to 7 extreme symptoms. The minimal score is 0 reflecting no positive symptoms to 49 reflecting that all items were extreme. Higher scores reflect more severe symptoms. Scores above 18 are usually clinically significant.</description>
        <time_frame>8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Olanzapine</title>
            <description>oral olanzapine 5-20mg per day for up to 52 weeks</description>
          </group>
          <group group_id="O2">
            <title>Risperidone</title>
            <description>oral risperidone 0.5mg to 6mg daily for up to 52 weeks</description>
          </group>
          <group group_id="O3">
            <title>Molindone</title>
            <description>oral molindone from 10-140mg/daily for up to 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in PANSS Negative Symptom Subscale at Week 8</title>
          <description>The PANSS (described above) includes 7 items that reflect negative psychotic symptoms such as amotivation and social withdrawal. As are all items within the PANSS, items are categorically rated by the clinician between 0 - no symptoms to 7 extreme symptoms. The minimal score is 0 reflecting no positive symptoms to 49 reflecting that all items were extreme. Higher scores reflect more severe symptoms. Scores above 18 are usually clinically significant.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="41"/>
                <count group_id="O3" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.3" spread="7.6"/>
                    <measurement group_id="O2" value="-5.1" spread="7.8"/>
                    <measurement group_id="O3" value="-5.8" spread="6.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Body Mass Index Change, kg/m2, at Week 8</title>
        <description>Change from baseline in Body Mass Index Change, kg/m2, at week 8, last observation was carried forward for individuals who withdrew from treatment early.</description>
        <time_frame>8 weeks</time_frame>
        <population>All randomized patients who took at least one dose of drug and had at least one post-baseline assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Olanzapine</title>
            <description>oral olanzapine 5-20mg per day for up to 52 weeks</description>
          </group>
          <group group_id="O2">
            <title>Risperidone</title>
            <description>oral risperidone 0.5mg to 6mg daily for up to 52 weeks</description>
          </group>
          <group group_id="O3">
            <title>Molindone</title>
            <description>oral molindone from 10-140mg/daily for up to 52 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Body Mass Index Change, kg/m2, at Week 8</title>
          <description>Change from baseline in Body Mass Index Change, kg/m2, at week 8, last observation was carried forward for individuals who withdrew from treatment early.</description>
          <population>All randomized patients who took at least one dose of drug and had at least one post-baseline assessment.</population>
          <units>kg/m2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="41"/>
                <count group_id="O3" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.27" spread="1.51"/>
                    <measurement group_id="O2" value="2.20" spread="1.24"/>
                    <measurement group_id="O3" value="0.15" spread="1.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>8 weeks, Systematic events</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Olanzapine</title>
          <description>oral olanzapine 5-20mg per day for up to 52 weeks</description>
        </group>
        <group group_id="E2">
          <title>Risperidone</title>
          <description>oral risperidone 0.5mg to 6mg daily for up to 52 weeks</description>
        </group>
        <group group_id="E3">
          <title>Molindone</title>
          <description>oral molindone from 10-140mg/daily for up to 52 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Psychiatric Hospitalization</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="35"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="41"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Suicidal Thoughts (life-threatening)</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="36" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blurred Vision</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="41"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="41"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Increase in appetite</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="35"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="41"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="35"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="41"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Menstrual Irregularities</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Sedation/Drowsiness</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="35"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="41"/>
                <counts group_id="E3" events="16" subjects_affected="16" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>weight gain</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="35"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="41"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Akathisia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="35"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="41"/>
                <counts group_id="E3" events="17" subjects_affected="17" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Dystonia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="35"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="41"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="35"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="41"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="35"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E3" events="9" subjects_affected="9" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="35"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="41"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="35"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="41"/>
                <counts group_id="E3" events="9" subjects_affected="9" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The most significant weakness of this study was the sample size, which was sufficient only to detect large differences across the three treatments and limited our ability to identify predictors of response or adverse effects.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Linmarie Sikich, MD</name_or_title>
      <organization>UNC Chapel Hill</organization>
      <phone>919-972-9744</phone>
      <email>lsikich@med.unc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

